Table 1. Clinical features of 18 AL... | American Society of Hematology

Table 1.

Clinical features of 18 AL amyloidosis patients with factor X deficiency and bleeding manifestations

Patient no.	Factor X, %	INR	aPTT (s)	Site of bleeding^*
Patient no.	Factor X, %	INR	aPTT (s)	Skin	Proc	GI/GU	TFN	SPL	Fatal
1	< 10	2.96	57	+	+
2	10	1.64	41			+
3	12	1.37	28	+
4	13	1.56	31	+	+		+
5	16	1.66	36	+	+		+		+
6	16	2.41	47		+	+	+		+
7	17	1.89	47				+	+
8	17	1.79	42		+		+
9	23	1.74	41					+
10	29	1.12	25	+
11	31	1.68	39			+
12	35	1.32	33			+
13	37	1.49	47	+	+		+
14	38	1.49	33			+
15	40	1.13	36	+
16	41	1.07	23			+
17	42	1.26	42	+
18	47	1.07	31	+

Patient no.	Factor X, %	INR	aPTT (s)	Site of bleeding^*
Patient no.	Factor X, %	INR	aPTT (s)	Skin	Proc	GI/GU	TFN	SPL	Fatal
1	< 10	2.96	57	+	+
2	10	1.64	41			+
3	12	1.37	28	+
4	13	1.56	31	+	+		+
5	16	1.66	36	+	+		+		+
6	16	2.41	47		+	+	+		+
7	17	1.89	47				+	+
8	17	1.79	42		+		+
9	23	1.74	41					+
10	29	1.12	25	+
11	31	1.68	39			+
12	35	1.32	33			+
13	37	1.49	47	+	+		+
14	38	1.49	33			+
15	40	1.13	36	+
16	41	1.07	23			+
17	42	1.26	42	+
18	47	1.07	31	+

Sites of bleeding included significant subcutaneous or soft tissue hemorrhage (Skin); unusual bleeding from a central venous line placement, biopsy, or other surgical procedure (Proc); gastrointestinal bleeding or hematuria (GI/GU); bleeding that required transfusion (TFN); intrasplenic hemorrhage (SPL); or bleeding associated with or contributing to mortality (Fatal).

View Large

This Feature Is Available To Subscribers Only